Efficacy and safety of Serenoa repens in benign prostatic disorders: a systematic review of recent clinical evidence.

raised concerns regarding the integrity of the randomization process, as evidenced by near-significant differences in baseline characteristics between groups – the S. repens treatment group had almost statistically worse prostate volume, Charlson Comorbidity Index, and urinary symptoms than the Prostaflog group – as well as unexplained discrepancies in group sample sizes. 44 In our opinion, these methodological shortcomings necessitated the exclusion of these studies from the primary analysis in order to preserve the rigour and credibility of our conclusions.

also in 1,659 other papers